Anti-inflammatory effects of vinpocetine in atherosclerosis and ischemic stroke: A review of the literature

Molecules

Volumn 20, Issue 1, 2015, Pages 335-347

  Zhang, Linjie ^a   Yang, Li ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Atherosclerosis; Inflammatory response; Ischemic stroke; Vinpocetine

Indexed keywords

ANTIINFLAMMATORY AGENT; VINCA ALKALOID; VINPOCETINE;

ATHEROSCLEROSIS; BRAIN ISCHEMIA; HUMAN; IMMUNOLOGY; STROKE;

ANTI-INFLAMMATORY AGENTS; ATHEROSCLEROSIS; BRAIN ISCHEMIA; HUMANS; STROKE; VINCA ALKALOIDS;

EID: 84921671068     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules20010335     Document Type: Review

References (56)

1. WHO. The Top 10 Causes of Death. Available online: http://www.who.int/mediacentre/factsheets/ (accessed on 8 June 2014).
2. Lozano, R.; Naghavi, M.; Foreman, K.; Lim, S.; Shibuya, K.; Aboyans, V.; Abraham, J.; Adair, T.; Aggarwal, R.; Ahn, S.Y.; et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the global burden of disease study 2010. Lancet 2012, 380, 2095-2128.
3. Go, A.S.; Mozaffarian, D.; Roger, V.L.; Benjamin, E.J.; Berry, J.D.; Borden, W.B.; Bravata, D.M.; Dai, S.; Ford, E.S.; Fox, C.S.; et al. Heart disease and stroke statistics-2013 update: A report from the american heart association. Circulation 2013, 127, e6-e245.
4. Adams, H.P., Jr.; Bendixen, B.H.; Kappelle, L.J.; Biller, J.; Love, B.B.; Gordon, D.L.; Marsh, E.E., 3rd. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. Toast. Trial of org 10172 in acute stroke treatment. Stroke 1993, 24, 35-41.
5. Ross, R. Atherosclerosis-An inflammatory disease. N. Engl. J. Med. 1999, 340, 115-126.
6. Libby, P. Inflammation in atherosclerosis. Nature 2002, 420, 868-874.
7. Hansson, G.K. Inflammation and immune response in atherosclerosis. Curr. Atheroscler. Rep. 1999, 1, 150-155.
8. Candelario-Jalil, E. Injury and repair mechanisms in ischemic stroke: Considerations for the development of novel neurotherapeutics. Curr. Opin. Investig. Drugs 2009, 10, 644-654.
9. Macrez, R.; Ali, C.; Toutirais, O.; le Mauff, B.; Defer, G.; Dirnagl, U.; Vivien, D. Stroke and the immune system: From pathophysiology to new therapeutic strategies. Lancet Neurol. 2011, 10, 471-480.
10. Endres, M.; Engelhardt, B.; Koistinaho, J.; Lindvall, O.; Meairs, S.; Mohr, J.P.; Planas, A.; Rothwell, N.; Schwaninger, M.; Schwab, M.E.; et al. Improving outcome after stroke: Overcoming the translational roadblock. Cerebrovasc. Dis. 2008, 25, 268-278.
11. Iadecola, C.; Anrather, J. The immunology of stroke: From mechanisms to translation. Nat. Med. 2011, 17, 796-808.
12. Murray, K.N.; Buggey, H.F.; Denes, A.; Allan, S.M. Systemic immune activation shapes stroke outcome. Mol. Cell. Neurosci. 2013, 53, 14-25.
13. Dabek, J.; Kulach, A.; Gasior, Z. Nuclear factor κ-light-chain-enhancer of activated b cells (NF-κB): A new potential therapeutic target in atherosclerosis? Pharmacol. Rep. 2010, 62, 778-783.
14. Xu, L.; Zhan, Y.; Wang, Y.; Feuerstein, G.Z.; Wang, X. Recombinant adenoviral expression of dominant negative IκBα protects brain from cerebral ischemic injury. Biochem. Biophys. Res. Commun. 2002, 299, 14-17.
15. Zhang, W.; Potrovita, I.; Tarabin, V.; Herrmann, O.; Beer, V.; Weih, F.; Schneider, A.; Schwaninger, M. Neuronal activation of NF-κB contributes to cell death in cerebral ischemia. J. Cereb. Blood Flow Metab. 2005, 25, 30-40.
16. Ning, M.; Zhou, Y.; Chen, G.; Mei, X. Preparation and in vitro/in vivo evaluation of vinpocetine elementary osmotic pump system. Adv. Pharmacol. Sci. 2011, 2011, doi:10.1155/2011/385469.
17. Vinpocetine. Monograph. Altern. Med. Rev. 2002, 7, 240-243.
18. Jeon, K.I.; Xu, X.; Aizawa, T.; Lim, J.H.; Jono, H.; Kwon, D.S.; Abe, J.; Berk, B.C.; Li, J.D.; Yan, C. Vinpocetine inhibits NF-κB-dependent inflammation via an ikk-dependent but pde-independent mechanism. Proc. Natl. Acad. Sci. USA 2010, 107, 9795-9800.
19. Beavo, J.A. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol. Rev. 1995, 75, 725-748.
20. Zhao, Y.Y.; Yu, J.Z.; Li, Q.Y.; Ma, C.G.; Lu, C.Z.; Xiao, B.G. Tspo-specific ligand vinpocetine exerts a neuroprotective effect by suppressing microglial inflammation. Neuron Glia Biol. 2011, 7, 187-197.
21. Torres, K.J.; Gottle, P.; Kremer, D.; Rivera, J.F.; Aguirre-Cruz, L.; Corona, T.; Hartung, H.P.; Kury, P. Vinpocetine inhibits oligodendroglial precursor cell differentiation. Cell. Physiol. Biochem. 2012, 30, 711-722.
22. Ammirati, E.; Moroni, F.; Magnoni, M.; Camici, P.G. The role of T and B cells in human atherosclerosis and atherothrombosis. Clin. Exp. Immunol. 2014, doi:10.1111/cei.12477.
23. Dong, Z.M.; Chapman, S.M.; Brown, A.A.; Frenette, P.S.; Hynes, R.O.; Wagner, D.D. The combined role of p- and e-selectins in atherosclerosis. J. Clin. Investig. 1998, 102, 145-152.
24. Leeuwenberg, J.F.; Smeets, E.F.; Neefjes, J.J.; Shaffer, M.A.; Cinek, T.; Jeunhomme, T.M.; Ahern, T.J.; Buurman, W.A. E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 1992, 77, 543-549.
25. Poole, J.C.; Florey, H.W. Changes in the endothelium of the aorta and the behaviour of macrophages in experimental atheroma of rabbits. J. Pathol. Bacteriol. 1958, 75, 245-251.
26. Collins, T.; Cybulsky, M.I. NF-κB: Pivotal mediator or innocent bystander in atherogenesis? J. Clin. Investig. 2001, 107, 255-264.
27. Berdeaux, A.; Loueslati, E.; Gerard, J.L.; Pussard, E.; Giudicelli, J.F. Evaluation of the natriuretic and beta-adrenoceptor-blocking effects of tienoxolol in normal volunteers. Fundam. Clin. Pharmacol. 1988, 2, 441-454.
28. Park, H.J.; Zhang, Y.; Georgescu, S.P.; Johnson, K.L.; Kong, D.; Galper, J.B. Human umbilical vein endothelial cells and human dermal microvascular endothelial cells offer new insights into the relationship between lipid metabolism and angiogenesis. Stem Cell Rev. 2006, 2, 93-102.
29. Zhuang, J.; Peng, W.; Li, H.; Lu, Y.; Wang, K.; Fan, F.; Li, S.; Xu, Y. Inhibitory effects of vinpocetine on the progression of atherosclerosis are mediated by AKT/NF-κB dependent mechanisms in apoe-/-mice. PLoS One 2013, 8, e82509.
30. Cai, Y.; Knight, W.E.; Guo, S.; Li, J.D.; Knight, P.A.; Yan, C. Vinpocetine suppresses pathological vascular remodeling by inhibiting vascular smooth muscle cell proliferation and migration. J. Pharmacol. Exp. Ther. 2012, 343, 479-488.
31. Gerthoffer, W.T. Mechanisms of vascular smooth muscle cell migration. Circ. Res. 2007, 100, 607-621.
32. Bonoczk, P.; Gulyas, B.; Adam-Vizi, V.; Nemes, A.; Karpati, E.; Kiss, B.; Kapas, M.; Szantay, C.; Koncz, I.; Zelles, T.; et al. Role of sodium channel inhibition in neuroprotection: Effect of vinpocetine. Brain Res. Bull. 2000, 53, 245-254.
33. Szilagyi, G.; Nagy, Z.; Balkay, L.; Boros, I.; Emri, M.; Lehel, S.; Marian, T.; Molnar, T.; Szakall, S.; Tron, L.; et al. Effects of vinpocetine on the redistribution of cerebral blood flow and glucose metabolism in chronic ischemic stroke patients: A pet study. J. Neurol. Sci. 2005, 229-230, 275-284.
34. Goncalves, I.; Gronholdt, M.L.; Soderberg, I.; Ares, M.P.; Nordestgaard, B.G.; Bentzon, J.F.; Fredrikson, G.N.; Nilsson, J. Humoral immune response against defined oxidized low-density lipoprotein antigens reflects structure and disease activity of carotid plaques. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 1250-1255.
35. Lichtman, A.H.; Binder, C.J.; Tsimikas, S.; Witztum, J.L. Adaptive immunity in atherogenesis: New insights and therapeutic approaches. J. Clin. Investig. 2013, 123, 27-36.
36. De Boer, O.J.; van der Wal, A.C. FOXP3+ regulatory T cells in vulnerable atherosclerotic plaques. Int. J. Cardiol. 2010, 145, 161.
37. Burioni, R.; Canducci, F.; Saita, D.; Perotti, M.; Mancini, N.; de Marco, D.; Clementi, N.; Chieffo, A.; Denaro, M.; Cianflone, D.; et al. Antigen-driven evolution of b lymphocytes in coronary atherosclerotic plaques. J. Immunol. 2009, 183, 2537-2544.
38. Gerondakis, S.; Fulford, T.S.; Messina, N.L.; Grumont, R.J. NF-κB control of T cell development. Nat. Immunol. 2014, 15, 15-25.
39. Magnus, T.; Wiendl, H.; Kleinschnitz, C. Immune mechanisms of stroke. Curr. Opin. Neurol. 2012, 25, 334-340.
40. Bereczki, D.; Fekete, I. Vinpocetine for acute ischaemic stroke. Cochrane Database Syst. Rev. 2008, doi:10.1002/14651858.CD000480.pub2.
41. Liu, N.; Wei, W.Z.W.; Wei, Y.; Yin, W. Efficacy and safety of vinpocetine in treatment of patients with acute cerebral infarction. Chin. J. Neuromed. 2014, 13, 4.
42. Patyar, S.; Prakash, A.; Modi, M.; Medhi, B. Role of vinpocetine in cerebrovascular diseases. Pharmacol. Rep. 2011, 63, 618-628.
43. Karpati, E.; Szporny, L. General and cerebral haemodynamic activity of ethyl apovincaminate. Arzneimittel-Forschung 1976, 26, 1908-1912.
44. Santos, M.S.; Duarte, A.I.; Moreira, P.I.; Oliveira, C.R. Synaptosomal response to oxidative stress: Effect of vinpocetine. Free Radic. Res. 2000, 32, 57-66.
45. Veenman, L.; Gavish, M. The peripheral-type benzodiazepine receptor and the cardiovascular system. Implications for drug development. Pharmacol. Ther. 2006, 110, 503-524.
46. Tarnok, K.; Kiss, E.; Luiten, P.G.; Nyakas, C.; Tihanyi, K.; Schlett, K.; Eisel, U.L. Effects of vinpocetine on mitochondrial function and neuroprotection in primary cortical neurons. Neurochem. Int. 2008, 53, 289-295.
47. Marsh, B.J.; Williams-Karnesky, R.L.; Stenzel-Poore, M.P. Toll-like receptor signaling in endogenous neuroprotection and stroke. Neuroscience 2009, 158, 1007-1020.
48. Tang, S.C.; Arumugam, T.V.; Xu, X.; Cheng, A.; Mughal, M.R.; Jo, D.G.; Lathia, J.D.; Siler, D.A.; Chigurupati, S.; Ouyang, X.; et al. Pivotal role for neuronal toll-like receptors in ischemic brain injury and functional deficits. Proc. Natl. Acad. Sci. USA 2007, 104, 13798-13803.
49. Zotti, T.; Uva, A.; Ferravante, A.; Vessichelli, M.; Scudiero, I.; Ceccarelli, M.; Vito, P.; Stilo, R. TRAF7 protein promotes Lys-29-linked polyubiquitination of IκB kinase (IKKγ)/NF-κB essential modulator (NEMO) and p65/Rela protein and represses NF-κB activation. J. Biol. Chem. 2011, 286, 22924-22933.
50. Konsman, J.P.; Drukarch, B.; van Dam, A.M. (Peri)vascular production and action of pro-inflammatory cytokines in brain pathology. Clin. Sci. 2007, 112, 1-25.
51. Worthmann, H.; Tryc, A.B.; Goldbecker, A.; Ma, Y.T.; Tountopoulou, A.; Hahn, A.; Dengler, R.; Lichtinghagen, R.; Weissenborn, K. The temporal profile of inflammatory markers and mediators in blood after acute ischemic stroke differs depending on stroke outcome. Cerebrovasc. Dis. 2010, 30, 85-92.
52. Zheng, Z.; Yenari, M.A. Post-ischemic inflammation: Molecular mechanisms and therapeutic implications. Neurol. Res. 2004, 26, 884-892.
53. Kleinschnitz, C.; Schwab, N.; Kraft, P.; Hagedorn, I.; Dreykluft, A.; Schwarz, T.; Austinat, M.; Nieswandt, B.; Wiendl, H.; Stoll, G. Early detrimental t-cell effects in experimental cerebral ischemia are neither related to adaptive immunity nor thrombus formation. Blood 2010, 115, 3835-3842.
54. De Oliveira, A.C.; Candelario-Jalil, E.; Langbein, J.; Wendeburg, L.; Bhatia, H.S.; Schlachetzki, J.C.; Biber, K.; Fiebich, B.L. Pharmacological inhibition of akt and downstream pathways modulates the expression of COX-2 and mPGES-1 in activated microglia. J. Neuroinflamm. 2012, 9, doi:10.1186/1742-2094-9-2.
55. Wang, Q.; Tang, X.N.; Yenari, M.A. The inflammatory response in stroke. J. Neuroimmunol. 2007, 184, 53-68.
56. Kleinschnitz, C.; Kraft, P.; Dreykluft, A.; Hagedorn, I.; Gobel, K.; Schuhmann, M.K.; Langhauser, F.; Helluy, X.; Schwarz, T.; Bittner, S.; et al. Regulatory T cells are strong promoters of acute ischemic stroke in mice by inducing dysfunction of the cerebral microvasculature. Blood 2013, 121, 679-691.